National Specialty Pharmacy, LLC v. One Way Drug, LLC

CourtDistrict Court, D. Nevada
DecidedJune 9, 2022
Docket2:21-cv-01082
StatusUnknown

This text of National Specialty Pharmacy, LLC v. One Way Drug, LLC (National Specialty Pharmacy, LLC v. One Way Drug, LLC) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
National Specialty Pharmacy, LLC v. One Way Drug, LLC, (D. Nev. 2022).

Opinion

1 UNITED STATES DISTRICT COURT 2 DISTRICT OF NEVADA 3 National Specialty Pharmacy, LLC and Case No.: 2:21-cv-01082-JAD-VCF Giving Home Healthcare, LLC, 4 Plaintiffs 5 Order Denying Motion for Attorney’s Fees v. 6 [ECF Nos. 39, 41, 45] One Way Drug LLC d/b/a Partell Pharmacy, 7 et al.,

8 Defendants

9 National Specialty Pharmacy and Giving Home Healthcare sued their former employee 10 William Tilghman and his new employers One Way Drug (Partell)1 and Advanced Care Group 11 (ACG), alleging that they misappropriated trade secrets. Last year, I granted the defendants’ 12 motions to dismiss the plaintiffs’ two federal claims and declined to exercise supplemental 13 jurisdiction over the remaining state-law claims. ACG now moves for attorney’s fees and costs. 14 Partell and Tilghman join ACG’s motion, seeking to recover their own fees and costs. 15 In its fees motion, ACG relies on the federal Defend Trade Secrets Act (DTSA), the very 16 statute under which the plaintiffs brought their now-dismissed claim, to support their entitlement 17 to attorney’s fees and costs, arguing that the plaintiffs brought that claim in bad faith. The 18 plaintiffs dispute that they acted in bad faith, contend that this court lacks jurisdiction to award 19 fees and costs, and argue that the defendants were not prevailing parties on the DTSA claim and 20 therefore cannot benefit from its fees provision. The defendants alternatively rely on 28 U.S.C. 21 § 1927 and various procedural and local rules—some of which don’t exist—to support their fees 22

23 1 One Way Drug, LLC conducts business as Partell Pharmacy. I follow the parties’ lead and refer to that defendant as “Partell.” 1 argument. Because this court lacks subject-matter jurisdiction to award fees under the DTSA 2 and none of the other bases proposed by ACG apply, I deny the motion. 3 Discussion 4 I. The court lacks subject-matter jurisdiction to award fees and costs under the DTSA.

5 ACG urges that it is entitled to attorney’s fees under the DTSA because the plaintiffs 6 pursued their DTSA claim in bad faith.2 Under the DTSA, “if a claim of [] misappropriation is 7 made in bad faith, . . . [a court may] award reasonable attorney’s fees to the prevailing party.”3 8 ACG mistakenly states that the DTSA “requires an award of attorneys’ fees,”4 but the language 9 of the statute is discretionary, clearly stating that “a court may” award attorney’s fees.5 Even 10 still, I cannot exercise such discretion because I lack subject-matter jurisdiction to award 11 attorney’s fees under the DTSA. Earlier in this case, the defendants filed separate motions to 12 dismiss, arguing that this court lacks subject-matter jurisdiction over the plaintiffs’ DTSA claim.6 13 At the hearing in which I dismissed the plaintiffs’ federal claims—including the DTSA claim—I 14 concluded that they failed to allege facts to meet a critical interstate-commerce element of their

15 claims, noting that “[t]he plaintiffs have made no attempt to allege a nexus for their trade secrets 16 and their product, and they have not demonstrated that they can if given leave to amend.”7 I also 17 noted that “[t]his appears . . . to be a very state-law based case” and dismissed both federal 18

2 ECF No. 39 at 4–6. 19 3 18 U.S.C. § 1836(b)(3)(D). 20 4 ECF No. 39 at 5 (emphasis added). 21 5 18 U.S.C. § 1836(b)(3) (emphasis added) (“In a civil action brought under this subsection with respect to the misappropriation of a trade secret, a court may. . . award reasonable attorney’s fees 22 to the prevailing party.”). 6 ECF No. 19 at 3–7 (Partell’s motion); ECF No. 22 at 4–8 (ACG’s motion); ECF No. 28 at 2–6 23 (Tilghman’s motion). 7 ECF No. 42 at 22 (hearing transcript). 1 claims “that anchor[ed] this case here with federal[-]question jurisdiction.”8 But I didn’t specify 2 that I was dismissing the claims for lack of subject-matter jurisdiction. The Supreme Court has 3 held that “[d]ismissal for lack of subject-matter jurisdiction because of the inadequacy of the 4 federal claim is proper only when the claim is ‘so insubstantial, implausible, foreclosed by prior 5 decisions of this Court, or otherwise completely devoid of merit as not to involve a federal

6 controversy.”9 So because I found that the crux of the plaintiffs’ case was state-law based and 7 that federal jurisdiction was nonexistent, I now clarify that I concluded that the plaintiffs’ DTSA 8 claim was completely devoid of merit. So the dismissal was grounded in the lack of subject- 9 matter jurisdiction. And just as this court lacked subject-matter jurisdiction over the plaintiffs’ 10 DTSA claim, it likewise lacks jurisdiction to award attorney’s fees under that same statute.10 11 Although the Ninth Circuit hasn’t directly addressed the relationship between attorney’s 12 fees and subject-matter jurisdiction in the DTSA context, it has done so in other circumstances, 13 including tax and patent cases.11 In Latch v. United States, the Ninth Circuit held that “[a]s a 14 general rule, if a district court has wrongfully exercised subject[-]matter jurisdiction over a

15 dispute, the appellate court must vacate the district court’s decision, including any award of 16 17 18

19 8 Id. at 23. 20 9 Steel Co. v. Citizens for a Better Environment, 523 U.S. 83, 89 (1998) (quoting Oneida Indian Nation of N.Y. v. Cnty. of Oneida, 414 U.S. 661, 666 (1974)) (citing Romero v. Int’l Terminal 21 Operating Co., 358 U.S. 354, 359 (1959)). 10 See Smith v. Brady, 972 F.2d 1095, 1097 & n.3 (9th Cir. 1992) (citing Latch v. United States, 22 842 F.2d 1031, 1032 (9th Cir. 1988)) (discussing Latch and noting that “[t]he district court’s award of attorney’s fees was overturned . . . because the district court had wrongfully exercised 23 subject[-]matter jurisdiction over the dispute, and thus had no power to award attorney’s fees.”). 11 See 18 U.S.C. § 1836(b)(3); Dubil v. Rayford Camp & Co., 184 F.2d 899 (9th Cir. 1950). 1 attorney’s fees.”12 It follows that if a district court lacks subject-matter jurisdiction over a claim 2 brought under a certain statute, like here, it cannot award attorney’s fees under that same statute. 3 “An exception to this rule exists whe[n] the statute under which a party seeks attorney’s 4 fees contains an independent grant of jurisdiction.”13 But nothing in the DTSA allows the court 5 to retain jurisdiction over a dismissed DTSA claim for the purpose of awarding attorney’s fees.14

6 And even if this court had jurisdiction to award attorney’s fees, the DTSA requires that the 7 movant be the “prevailing party,”15 which ACG isn’t. The Ninth Circuit has interpreted 8 “prevailing party” to exclude defendants in cases “when dismissal is mandated by a lack of 9 subject[-]matter jurisdiction.”16 That is precisely the category that ACG falls into here.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
National Specialty Pharmacy, LLC v. One Way Drug, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/national-specialty-pharmacy-llc-v-one-way-drug-llc-nvd-2022.